Remibrutinib (LOU064): A selective potent oral BTK inhibitor with promising clinical safety and pharmacodynamics in a randomized phase I trial

Safe and effective new oral therapies for autoimmune, allergic, and inflammatory conditions remain a significant therapeutic need. Here, we investigate the human pharmacokinetics, pharmacodynamics (PDs), and safety of the selective, covalent Bruton’s tyrosine kinase (BTK) inhibitor, remibrutinib. St...

Descripción completa

Detalles Bibliográficos
Autores principales: Kaul, Martin, End, Peter, Cabanski, Maciej, Schuhler, Carole, Jakab, Annamaria, Kistowska, Magdalena, Kinhikar, Arvind, Maiolica, Alessio, Sinn, Angela, Fuhr, Rainard, Cenni, Bruno
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8504815/
https://www.ncbi.nlm.nih.gov/pubmed/33834628
http://dx.doi.org/10.1111/cts.13005

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8504815/
https://www.ncbi.nlm.nih.gov/pubmed/33834628
http://dx.doi.org/10.1111/cts.13005

Ejemplares similares